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Abstract
Background: Hyaluronic acid (HA) is present in many tissues; its presence in serum may be related to certain 
inflammatory conditions, tissue damage, sepsis, liver malfunction and some malignancies. In the present work, our 
goal was to investigate the significance of hyaluronic acid effect on erythrocyte flow properties. Therefore we 
performed in vitro experiments incubating red blood cells (RBCs) with several HA concentrations. Afterwards, in order 
to corroborate the pathophysiological significance of the results obtained, we replicated the in vitro experiment with ex 
vivo RBCs from diagnosed rheumatoid arthritis (RA) patients, a serum HA-increasing pathology.
Methods: Erythrocyte deformability (by filtration through nucleopore membranes) and erythrocyte aggregability (EA) 
were tested on blood from healthy donors additioned with purified HA. EA was measured by transmitted light and 
analyzed with a mathematical model yielding two parameters, the aggregation rate and the size of the aggregates. 
Conformational changes of cytoskeleton proteins were estimated by electron paramagnetic resonance spectroscopy 
(EPR).
Results: In vitro, erythrocytes treated with HA showed increased rigidity index (RI) and reduced aggregability, situation 
strongly related to the rigidization of the membrane cytoskeleton triggered by HA, as shown by EPR results. Also, a 
significant correlation (r: 0.77, p < 0.00001) was found between RI and serum HA in RA patients.
Conclusions: Our results lead us to postulate the hypothesis that HA interacts with the erythrocyte surface leading to 
modifications in erythrocyte rheological and flow properties, both ex vivo and in vitro.
Background
Elevated seric hyaluronic acid (HA) is a feature of certain
inflammatory conditions, notably rheumatoid arthritis
and scleroderma, and also accompanies tissue damage,
sepsis, liver malfunction and some malignancies [1-8].
Additionally, the employment of HA is currently sug-
gested in the therapy of arthritis, arthrosis, psoriasis, and
it is also included in treatments with cosmetic products
[9-12].
Being HA a macromolecule present in plasma, it could
interact with the red blood cell (RBC) surface, as it hap-
pens with albumin. In a previous work [13] we have dem-
onstrated that albumin adsorption impairs erythrocyte
rheology in a concentration-dependent fashion increas-
ing the erythrocyte rigidity index (RI). Such facts lead us
to hypothesize that the reduction in erythrocyte deform-
ability (RI increase) observed in serum HA-increasing
pathologies, could be due to HA interaction with RBC
surface which contributes to the impaired flow properties
observed in these pathologies [14,15].
We therefore conducted this study to investigate the
significance of serum HA effect on erythrocyte flow
properties.
We performed in vitro experiments incubating RBCs
from healthy donors with several HA concentrations.
Afterwards, in order to corroborate the obtained results,
we selected a serum HA-increasing pathology and repli-
cated the experiment ex vivo with RBCs from those
patients. We chose rheumatoid arthritis RA patients
because in an earlier paper we demonstrated a reduction
in erythrocyte RI that is in close correlation with the Dis-
ease Activity Score (DAS 28-4) index during the clinical
remission of the process [16].
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The Ethics Committee of the Facultad de Ciencias Médi-
cas, Universidad Nacional de Rosario, Argentina
approved the study protocol, and all participants signed
an informed consent according to the recommendations
of the Declaration of Helsinki [17].
Blood sample collection and laboratory assays
Blood samples of RA patients were obtained by venipunc-
ture and separated in 2 aliquots. One of them was col-
lected in tubes containing EDTA and assigned to
determine haematimetric indexes, plasmatic protein con-
centration and rheological parameters. The other was
collected in a dry tube and centrifuged 5 min at 5000
RPM in order to obtain serum for the serum concentra-
tion of HA.
a) Haematimetric indexes: Erythrocyte count was
assessed by a hæmocytometer and hæmoglobin by the
cyanmetahæmoglobin method. From these values, MCV
and MCHC were calculated.
b) Plasmatic immunoglobulin concentration: by radial
immunodiffusion.
c) Fibrinogen concentration: by commercial kinetic test
kit (Boehringer Mannheim, Germany).
d) HA assay: by an ELISA commercial test kit (CHU-
GAI quantitative test Kit), using HABP (HA Binding Pro-
tein) as capture molecule [18].
Haemorheological assays
a) Rigidity index (RI)
Whole blood from RA patients was centrifuged at 5000
RPM for 5 minutes, plasma and buffy coat were separated
and the erythrocytes were washed twice with PBS (0.12
M NaCl, 0.03 M H2KPO4/HNa2PO4 with 2 mg/ml glu-
cose).
Washed RBCs were resuspended (10% hæmatocrit) in
PBS with bovine albumin (0.25%) (Sigma Chemical Co.,
St.Louis, MO, USA) in order to prevent erythrocyte
aggregation.
Erythrocyte filtration was performed in a computerized
instrument using the Reid et al. technique [19]. Briefly, a
10% suspension of washed erythrocytes was passed
through a polycarbonate filter, 5 μm pore size (Nucleo-
pore Corp. USA), using a negative filtration pressure of
10 cm H2O. The flow time required for 1 ml of RBC sus-
pension to pass through the filter was measured. Results
were expressed as the rigidity index (RI) that is an estima-
tion of erythrocyte rigidity (inverse of erythrocyte
deformability) [20], defined as:
Where: Tb: time of passage of the cell suspension
through the filter; Ts: time of passage of an equal volume
of PBS; Htc: hæmatocrit (10%).
The erythrocyte deformability measurements are in
accordance to the International Committee for Standard-
ization in Haematology [21].
b) Erythrocyte aggregation
This parameter was measured in whole blood at native
hæmatocrit. An instrument [22] assembled as a model
designed by Tomita et al. [23] was used. In brief, it con-
sists of a densitometer head that detects light transmis-
sion changes in whole blood during the aggregation
process that follows a disaggregating agitation [24].
The registered data were analyzed with a mathematical
model allowing us to determine two parameters: 2k2n0,
which stands for the initial rate of the process, and s0/n0,
which estimates aggregation intensity and average roule-
aux size at process completion.
c) Erythrocyte membrane fluidity
Erythrocyte membrane fluidity was estimated by electron
paramagnetic resonance spectroscopy (EPR) using lipo-
soluble spin labels 5, 12 and 16- doxyl stearic acid (5-, 12-
, and 16-SASL, Sigma Chemical Co., St. Louis, MO, USA),
which sense the mobility of the acyl chains at different
depths in the lipid leaflet of the RBC membrane [25]. The
EPR spectra were obtained at 25 ± 1°C in a Bruker ER-200
spectrometer operating at X band (9800 MHz).
In the case of erythrocytes from RA patients, mem-
brane fluidity was assessed using the parallel component
of the nitrogen hyperfine tensor of 5-SASL (T//) as a rep-
resentative parameter of lipid chain rigidity. Thus,
increased T// values are indicative of decreased mem-
brane fluidity [26].
In the case of cells incubated in vitro with HA, we eval-
uated S5, S12 and S16 order parameters at different depths
of the lipid bilayer, from the spectra of 5, 12 or 16-SASL.
As in the previous case, increased S parameters indicate
decreased membrane fluidity.
HA purification
HA was purified from other acid mucopolysaccharides by
ecteola cellulose chromatography [27] and eluted with
0.05 N HCl. HA concentration in the eluate was colori-
metrically determined, through estimation of the
glucuronic acid content, by using carbazole in sulphuric
medium [28].
The elution solution was neutralized to pH 7.4 with
0.05 N NaOHRI Tb Ts Ts Htc= − ×( ) / ( ) /100
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- Erythrocyte incubation in hyaluronic acid solutions and RI 
determination
Blood samples were obtained from healthy adults by
venipuncture and collected in tubes containing EDTA
(1,146 mg/ml, Sigma Chemical Co., St.Louis, MO, USA)
as anticoagulant. Each sample was fractioned in 5 ali-
quots (1 ml). The first sample (control; n = 6) was addi-
tioned with 1 ml of neutralized elution solution and the
other ones with 1 ml of purified HA in rising concentra-
tions, yielding the following final nominal concentrations
(μg/ml): [HA1] = 50; [HA2] = 87; [HA3] = 109; [HA4] =
190 (n = 6). After 30 min incubation at 37°C, serum HA
concentration ([HA]s) and erythrocyte RI were deter-
mined for each sample in a similar way as for RA patients.
- Reversibility of HA-erythrocyte interaction
In order to test the reversibility of HA-erythrocyte inter-
action, RI was determined again in erythrocytes of each
sample after washing twice with PBS.
-Aggregability determination in erythrocytes incubated in HA
Blood samples were divided into two fractions; one of
them was added with purified HA to reach a final con-
centration similar to that found in serum of RA patients,
[HA] = 109 μg/ml (HA group; n = 15), and the other one
was added with the same volume of the the neutralized
elution solution (control group; n = 15). Both aliquots
were incubated for 30 min at 37°C. Afterwards, serum
concentration of HA was determined and erythrocyte
aggregability was measured as described previously.
EPR spin label studies of the cytoskeleton proteins in 
haemoglobin-free erythrocyte membranes In order to
obtain haemoglobin-free erythrocyte membranes, RBC's
from regular donors were subjected to hypotonic lysis in
sodium phosphate buffer 5 mM, pH 8 (for 30 min at 4°C)
and the pellet was thoroughly washed [29]. The mem-
brane samples were subdivided into two fractions. One of
them (HA group; n = 6) was added with purified HA to
reach concentrations similar to those found in serum of
RA patients, and the same volume of the elution solution
was added to the other fraction (control group; n = 6).
Both media had been previously neutralized to pH 7.4.
Both aliquots were incubated with the spin label 4-
maleimido-Tempo (Mal-Tempo, Sigma Chemical Co.,
St.Louis, MO, USA), at a concentration of 30-50 μg per
mg of protein, in the dark, at 4°C for 1 h.
The protein-specific spin-label Mal-Tempo is known to
bind covalently to cysteine sulfhydryl groups of cytoskel-
eton membrane proteins. W/S parameter, estimated from
the Mal-Tempo EPR spectrum [29], reflects two types of
membrane protein SH-binding sites for the spin label:
strongly and weakly immobilized sites (S and W sites,
respectively). Changes in the W/S parameter are indica-
tive of conformational changes in the cytoskeleton pro-
teins.
Ex vivo experiments
-RA Patients
One hundred female RA patients attending an outpatient
service at the Departamento de Reumatologia, Universi-
dad Nacional de Rosario, Argentina, were included in the
present study (mean age 48 ± 17 yr).
The patients were part of a follow-up study recruited
between the years 2000 and 2003 [13]. RA diagnosis was
established following the American College of Rheuma-
tology criteria [30-32]. Patients with cardiovascular or
liver disease, cancer, chronic infectious diseases, HIV
positive serology or diabetes mellitus as well as heavy
smokers (>20 cigarettes/day) and patients who were
under medication that could alter hæmorheological
blood properties, were dismissed. The laboratory process
has been described previously [13]. The clinic activity of
the disease was evaluated by means of the Disease Activ-
ity Score (DAS 28-4) [33].
Controls
The control group consisted of 40 female non-smoker
healthy volunteers, age-matched (mean: 43 ± 12 yr).
Statistical analysis
The Kruskal-Wallis' test was performed considering vari-
ables; RI: RI after washes; afterwards Mann-Whitney's U
Table 1: Erythrocyte aggregability in the presence of HA and its control (n = 15)
2k2n0 s0/n0
Control 1.98 ± 0.14 1.867 ± 0.015
HA Group 1.29** ± 0.21 1.866 ± 0.004
Data: mean ± standard deviation.
Degree of significance of the difference between groups: ** p < 0.01
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formed between RI and RI after washes for each group.
Data are presented as median and 95% confidence inter-
val (Figure 1).
Comparisons for aggregation parameters (2k2n0 and
s0n0) between HA and control groups were performed by
Student's t-test for paired data. Values are presented as
mean ± standard deviation (Table 1).
Differences in cytoskeleton protein conformation and
in lipid chain ordering at different levels of the membrane
between control and HA treated erythrocytes, assesed by
EPR, were analized using Wilcoxon test for paired data.
Results are expressed as median and 95% confidence
interval (Table 2).
The correlation between RI and [HA]s in RA patients
was estimated using Pearson product-moment correla-
tion coefficient. Values were presented as mean ± stan-
dard deviation (Table 3).
Pearson product-moment correlation coefficient was
also used to analyze the dependence of RI with [IgG],
[IgM], MHCM, T// and fibrinogen concentration in RA
patients.
Results
In vitro experiments
Figure 1 shows that the rigidity index is significantly
increased after incubation with HA at all the measured
[HA] range. There is a remarkable good correlation
between RI and [HA]s (rs: 0.996, p < 0.00001). Figure 1
also shows that after two washings, RI returns to control
values. Thus, it can be postulated that HA reduces eryth-
rocyte deformability reversibly and in a concentration
dependent manner.
Regarding aggregation properties, the results presented
in Table 1 indicate a significant decrease in the parameter
2k2n0 in erythrocytes incubated with HA, while no differ-
ences in the parameter s0/n0 are observed. This means
that the presence of HA in the incubation medium
diminishes the erythrocyte aggregation rate, without sig-
nificantly modifying the size of the aggregates.
Table 2 shows that the order parameters S, calculated
from the EPR spectra of liposoluble spin labels, do not
exhibit significant differences between HA group and
control group, indicating that the fluidity of the lipid
Rigidity Index (RI) of erythrocytes incubated in vitro with 
variable HA concentrations, and reversibility of HA effect
Figure 1 Rigidity Index (RI) of erythrocytes incubated in vitro with 
variable HA concentrations, and reversibility of HA effect. In vitro 
effect of several.hyaluronic acid (HA) concentrations on rigidity index 
(RI). Each sample was fractioned in 5 aliquots (1 ml). The first sample 
(control; n = 6) was additioned with 1 ml of neutralized elution solution 
and the other ones with 1 ml of purified HA in raising concentrations, 
yielding the following final nominal concentrations (μg/ml): [HA1] = 50; 
[HA2] = 87; [HA3] = 109; [HA4] = 190 (n = 6). As can be seen, after two 
washings, RI returns to control values. Data: median, C.I.95%: confidence 
interval. (n = 6). RI: Kruskal Wallis' test: H = 27.87; p < 0.0001. Post hoc 
tests were performed with Mann-Whitney's U between groups, p < 
0.05. RI after wash: Kruskal Wallis' test n.s.
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Table 2: HA effect on cytoskeleton protein conformation and on lipid chain order at different levels
[HA] μg/ml W/S S5 S12 S16
Control < 10 3.20
(3.10 -- 3.30)
0.693
(0.685--0.703)
0.525
(0.524--0.527)
0.230
(0.228--0.230)
HA Group 103
(100-105)
2.65*
(2.60 --2.70)
0.690
(0.677--0.707)
0.521
(0.520--0.524)
0.229
(0.225--0.233)
W/S: ratio of the spectral amplitudes of Mal-Tempo attached to strongly and weakly immobilized sulfhydryl groups.
S5, S12 and S16: 5, 12 or 16- doxyl stearic acid spin labels.
Data: median, C.I.95%: confidence interval. (n = 6).
Degree of significance of the difference between groups: * p < 0.05
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HA. Conversely, the W/S parameter, calculated from the
spectra of Mal-Tempo, was significantly diminished in
the HA group. This suggests that incubation with HA
introduces changes in the conformation of the cytoskele-
tal protein spectrin.
Ex vivo experiments
Previous analysis [16] performed on erythrocytes from
active RA patients (DAS 28-4 > 2,6) showed a good corre-
lation between disease activity and serum HA concentra-
tion [HA]s (Pearson product-moment correlation
coefficient (r) DAS 28-4 vs. [HA]s: 0.87, p < 0.0001). Table
3 shows that erythrocytes from the active RA patients
have a rigidity index significantly higher than those of the
control group, together with a significantly increased
[HA]s.
Subsequent correlation analyses were performed
between erythrocyte RI and intrinsic and extrinsic
parameters. It was found that RI has a significant correla-
tion with [HA]s (r: 0.77 p < 0.00001), while it does not
correlate either with lipid bilayer rigidity (T//) or with
internal viscosity (evaluated through MCHC). Also, there
was no significant correlation between RI and plasma
proteins, namely, IgG (r: 0.32, p > 0.05) and IgM (r: 0.33, p
> 0.05), and fibrinogen (r: 0.12, p > 0.05), which might be
adsorbed on cell surface modifying the membrane rheol-
ogy.
Discussion
Erythrocyte rigidity is a determining factor concerning
flow resistance, especially in microcirculation, where
RBCs must pass through capillaries of a diameter lower
than the cells. Even in macrocirculation, rigidity is a fac-
tor of flow resistance, thus contributing to the hipervis-
cosity syndrome.
HA is a glycosaminoglycan --a high molecular weight
polysaccharide--that, similarly to albumin, could interact
with the erythrocyte surface. Our hypothesis was that
this interaction could lead, in the same way that albumin
does, to a reduction in the flexibility of the membrane.
The verification of this hypothesis demanded to establish
a correlation between RI values and HA medium concen-
tration.
When blood from healthy donors was incubated with
several HA concentrations it was corroborated that HA
caused a significant decrease in erythrocyte deformability
(increase in RI) in a concentration-dependent manner
and reversibly-- this effect was reverted by washing the
treated cells.
In an earlier paper [16] we have demonstrated that
RBC's from RA patients presented a considerably
increased RI. In the same paper [16] it was corroborated
that RI is a reliable indicator for RA activity, given its sig-
nificant correlation with DAS 28-4 score.
Experiments performed on blood from RA patients in
different levels of activity of the disease showed that HA
was the only plasma factor that significantly affected
deformability; moreover, the expected correlation
between RI values and [HA]s was found (r: 0.77, p <
0.00001). The discrepancy of RI values in erythrocytes of
RA patients (Table 3) with those of erythrocytes incu-
bated with similar HA levels in the in vitro experiment
(Figure 1) should be attributed to the presence in plasma
of pathology dependent factors affecting the erythrocyte
rheology.
One of the techniques classically employed in RA diag-
nosis is erythrocyte sedimentation rate (ESR). This value
estimates mainly the rise in erythrocyte aggregation.
Rouleaux formation depends on medium and cell factors.
Consequently, its increase may be explained by the rise in
fibrinogen and/or globulin concentration and/or to the
modification of the erythrocyte surface properties.
In our in vitro experiments, it was observed that HA-
treated RBCs showed a lower aggregation rate (Table 1),
i.e., a lower tendency to form rouleaux in comparison to
controls. This fact implies that the increased ESR in
blood from RA patients could only be attributed to modi-
fications in plasma proteins and not to cell factors [33].
Table 3: Rigidity index and hyaluronic acid concentration in patients with active Rheumatoid Arthritis and their controls
[HA]s (μg/ml) RI
Controls (n = 40) 20.0 ± 9.0 7.0 ± 0.8
RA Patients (n = 100) 155.80 ± 44.0 11.0 ± 1.3
P < 0.00001 < 0.001
[HA]s: serum concentration of hyaluronic acid; RI: rigidity index; RA: rheumatoid arthritis.
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most important plasma protein-- is adsorbed on the
erythrocyte surface [13] and, unlike globulins and fibrin-
ogen, hinders the aggregation process. The corroboration
that HA presented a similar behaviour to that of albumin
constitutes a further support for the claimed hypothesis.
EPR spectroscopy allowed us to investigate the effects
caused by the in vitro interaction of HA with RBC mem-
brane. As shown in Table 2, order parameters did not
change significantly, indicating that the fluidity of the
lipid bilayer was not altered as a consequence of HA incu-
bation. On the contrary, the parameter W/S, calculated
from the spectrum of a protein spin label, revealed that
HA produces alterations in the spectrin structure of the
membrane cytoskeleton increasing the amount of
strongly immobilized sites. This result suggests that the
increase in erythrocyte rigidity is related to a stiffening of
the cytoskeleton. However, as HA only interacts with the
outer erythrocyte surface, we postulate that HA interac-
tion results in a protein organizational perturbation that
is translated to spectrin in the inner membrane surface.
Conclusions
Our experiments lead us to accept the hypothesis that
HA interacts with the erythrocyte surface, giving place to
modifications in erythrocyte rheological and flow prop-
erties.
Considering that HA is increased in inflammatory pro-
cesses and other malignancies, and that it is employed in
pharmacologic and cosmetic treatments, in all these
cases we claim that the effect of HA upon erythrocytes --
and thus on circulatory function-- should not be disre-
garded; in fact, special attention should be paid to this
matter.
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